Lupin Pharma Joins Hands With Endoceutics To Commercialise Intrarosa In Canada

Lupin Pharma, a subsidiary of drug major Lupin has partnered with Endoceutics, a women’s health focused biotech company, to commercialise Intrarosa in Canada.

Intrarosa is Endoceutic’s flagship product indicated for the treatment of postmenopausal vulvovaginal atrophy.

Intrarosa is Endoceutic’s flagship product indicated for the treatment of postmenopausal vulvovaginal atrophy.

Commenting on the partnership, Dr Sofia Mumtaz, President, Lupin Pharma Canada said, “We are very pleased to partner with Endoceutics to bring this long-awaited innovative product to the Canadian market. Intrarosa will not only expand and strengthen our product portfolio into Women’s Health in Canada but will cater to satisfy the unmet medical needs.”

“Intrarosa will not only expand and strengthen our product portfolio into Women’s Health in Canada but will cater to satisfy the unmet medical needs,” Sofia Mumtaz, President, Lupin Pharma Canada said.

Lupin said it is estimated that over 50 per cent of post-menopausal women suffer from the symptoms of vulvovaginal atrophy and that less than 10 per cent of these women are treated with prescription medicines.

Intrarosa was developed in Quebec City, Canada by Endoceutics and will be manufactured in their facilities in Mont Saint Hilaire, Canada. Intrarosa is indicated for postmenopausal vulvovaginal atrophy, it is a vaginal ovule containing 6.5 mg of Prasterone. It comes in blister packs of 28 ovules, with 7 reusable applicators.

The recommended dose is one vaginal ovule inserted once a day at bedtime, using the provided applicator or fingers. It is estimated that over 50% of postmenopausal women suffer from the symptoms of vulvovaginal atrophy and that less than 10% of these women are treated with prescription medicines.

Facebook Comments